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Abstract
Objective
Dysphagia develops with low frequency in patients with dermatomyositis. Our objective was
to determine the clinical and laboratory features that can estimate the development of dys-
phagia in dermatomyositis.
Methods
This study included 92 Japanese patients with adult-onset dermatomyositis. The associa-
tions between dysphagia and clinical and laboratory features including disease-specific
autoantibodies determined by immunoprecipitation assays were analyzed.
Results
Videofluoroscopy swallow study (VFSS) was performed for all patients with clinical dyspha-
gia (n = 13, 14.1%) but not for patients without clinical dysphagia. Typical findings of dys-
phagia (pharyngeal pooling, n = 11 and/or nasal regurgitation, n = 4) was detected by VFSS
in all patients with clinical dysphagia. Eleven patients with dysphagia (84.6%) had anti-tran-
scription intermediary factor 1γ (TIF-1γ) antibody. By univariate analysis, the average age
and the male to female ratio, internal malignancy, and anti-TIF-1γ antibody were signifi-
cantly higher and the frequency of interstitial lung diseases and manual muscle testing
(MMT) scores of sternomastoid and dertoid muscles were significantly lower in patients with
dysphagia than in patients without dysphagia. Among patients with anti-TIF-1γ antibody,
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the mean age, the ratios of male to female and internal malignancy were significantly higher
and mean MMT scores of sternomastoid muscle were significantly lower in patients with
dysphagia compared with patients without dysphagia. By multivariable analysis, the risk of
dysphagia was strongly associated with the existence of internal malignancy and ant-TIF-
1γ antibody and was also associated with reduced scores of manual muscle test of sterno-
mastoid muscle. Dysphagia was markedly improved after the treatment against myositis in
all 13 patients.
Conclusion
These findings indicate that dysphagia can develop frequently in patients with internal
malignancy, anti-TIF-1γ antibody, or severe muscle weakness of sternomastoid muscle.
Introduction
Polymyositis (PM) and dermatomyositis (DM) are autoimmune connective tissue diseases
characterized by symmetric proximal myositis. PM and DM are similar diseases, but DM can
be distinguished from PM via the presence of specific skin lesion such as heliotrope rash or
Gottron’s papule/sign. Clinical manifestations of DM are heterogeneous and interstitial pneu-
monia and internal malignancy affect the prognosis.
Dysphagia has been reported to develop in 10 to 73% of patients with inflammatory myopa-
thy during the clinical course, especially in inclusion body myositis [1–3]. The dysphagia in
this disease primarily affects the skeletal muscle-activated oropharyngeal phase of swallowing.
This may occur due to weakness of oropharyngeal, laryngeal, and esophageal musculature.
Recognition of dysphagia is important, since dysphagia is associated with various clinical fea-
tures such as nasal speech, hoarseness, regurgitation, nutritious deficits, aspiration pneumonia,
impaired quality of life, and poor prognosis. It has been reported that dysphagia involvement is
more frequent in patients with internal malignancy among patients with DM [4, 5].
Recent studies demonstrated that myositis-specific autoantibodies are associated with spe-
cific clinical phenotype [6]. Among them, antibodies against a 155-kd protein (anti-p155 Ab)
and a 155/140-kd doublet (anti-155/140 Ab) have shown a significant association with malig-
nancy in adult patients with DM [7–9]. Transcription intermediary factor 1γ (TIF-1γ) and
TIF-1α/γ have been considered to be the autoantigen target of these Abs, respectively [10]. A
patient with DM who was positive for anti-TIF-1γ Ab had 27-fold higher odds of having malig-
nancy compared with a patient who was negative for the Abs [11]. On the other hand, pulmo-
nary involvement is frequently seen in patients with anti-aminoacyl transfer RNA synthetase
(ARS) Abs [12] or anti-melanoma differentiation-associated protein 5 (MDA-5) Ab [13, 14].
DM patients with anti-Mi-2 Abs typically do not have interstitial lung disease (ILD) or internal
malignancy and have a good prognosis [15]. However, the association between autoantibodies
and the involvement of dysphagia remains unclear. Furthermore, to our best knowledge,
almost no studies have analyzed the associated clinical or laboratory features focused on dys-
phagia in DM.
In this study, we assessed the association between the oropharyngeal involvement and clini-
cal or laboratory features including recently identified autoantibodies.
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Materials and Methods
Patients
Ninety-two Japanese patients with DM (72 females and 20 males; age (mean ± SD), 54.9 ± 16.2
years) who visited Kanazawa University Hospital between January, 2004 and December, 2015
were included in this study. Eighty patients fulfilled the criteria of Bohan and Peter [16, 17],
while the remaining 12 did not fulfil the criteria, but fulfilled Sontheimer’s criteria [18], due
to the absence of clinical muscle symptoms and presence of subsistent clinical skin eruptions.
Mean disease duration was 9.7 ± 14.9 months. At the time of evaluation, no patients were
receiving oral prednisolone therapy and other immunosuppressive drugs.
Clinical assessment
Complete medical histories, physical examinations, and laboratory tests were conducted for all
patients during the first visit, with limited evaluations during follow-up visits. The objective
symptoms of pharyngeal pooling, nasal regurgitation, and nasal speech were evaluated by oto-
rhinolaryngologists and speech therapists. The patients were diagnosed as having ILD accord-
ing to the results of chest radiography, chest computed tomography, and pulmonary function
testing. Serum Krebs von den Lungen-6 (KL-6) levels as a serum marker of ILD were deter-
mined by ELISA as described previously [19]. Presence of internal malignancy was carefully
examined using computed tomography, gastrointestinal fiberscope, gallium scintigraphy and
other procedures according to need. The medical ethics committee of Kanazawa University
approved this study protocol (No. 961, An investigation of rehabilitation for dermatomyositis/
polymyositis). An informed written consent was obtained from each patient.
Videofluoroscopy swallow study (VFSS)
The existence of dysphagia was confirmed by VFSS in patients with clinical dysphagia. A fluo-
roscopy unit (Siemens Polystar digital unit- Siemens AG, Erlangen, Germany) connected to a
medical high definition medical quality videorecorder was used. Videofluoroscopy studies
were performed in a lateral position with the patient in a seated position. The patient was
asked to swallow a food and/or liquid bolus of high density (EZPaque 100% wpv) barium sul-
phate suspension. Images were acquired at 15 pulses/s.
Myositis disease activity assessment
To assess disease activity based on individual organ systems, the Myositis Disease Activity
Assessment Visual Analogue Scales (MYOACT VAS) portion of the Myositis Disease Activity
Tool [20] was used. The MYOACT assessment utilizes separate 100-mm VAS to gauge the
physician’s evaluation of disease activity in several discrete domains. Involvement of all non-
muscle organ systems (constitutional, cardiac, pulmonary, gastrointestinal, skeletal, and cuta-
neous) was also evaluated using the composite extra-skeletal muscle VAS score. An additional
VAS measure, the global VAS score, was used to rate overall disease activity.
Immunoprecipitation assays
Immunoprecipitation assays were performed to identify autoantibodies using extracts of the
leukemia cell line, K562, as previously described [13]. Using this method, 23 of 92 patients
were positive for anti-ARS Ab, 26 patients were positive for anti-TIF-1γ Ab, 3 patients were
positive for anti-Mi-2 Ab, 15 patients were positive for anti-MDA-5 Ab, 5 patients were posi-
tive for anti-SS-A (Ro60) Ab, 5 patients were positive for anti-U1 ribonucleoprotein (U1 RNP)
Ab, and a patient was positive for anti-signal recognition particle (SRP) Ab. Four patients were
Dysphagia in Dermatomyositis
PLOS ONE | DOI:10.1371/journal.pone.0154746 May 11, 2016 3 / 11
positive both for anti-ARS Ab and anti-SS-A Ab. One patient was positive both for anti-MDA-
5 Ab and anti-U1 RNP Ab.
Statistical analysis
Statistical analysis was performed using Student’s t test or Fisher’s exact probability test. The
relationship between the involvement of dysphagia and explanatory variables was analysed
using multivariable analysis (logistic regression). Significant variables after univariate regres-
sion (p<0.15) were entered into a stepwise multivariate model. Results are expressed as the OR
with 95% CI. A p-value<0.05 was considered indicative of statistical significance.
Results
Videofluoroscopy swallow study (VFSS)
We considered that 13 patients had clinical dysphagia by history taking and examination of
otolaryngologists and speech therapists. To confirm the existence of dysphagia, VFSS was per-
formed in these 13 patients and all patients showed the typical findings of dysphagia (pharyn-
geal pooling; n = 11 and/or nasal regurgitation; n = 4). Dysphagia was found at the pharyngeal
phases, but not at oral stage or esophageal stage in all of these patients. A representative case of
pharyngeal pooling is shown as Fig 1A and S1 Fig. VFSS of a representative case of nasal pool-
ing was also shown before and after treatment of DM (Fig 1B and S2 Fig). Before treatment,
she showed nasal regurgitation at pharyngeal phases. This patient also developed nasal speech,
probably due to the loss of pharyngo-oesophageal muscle tone. However, nasal regurgitation
detected by VFSS and nasal speech were diminished after oral treatment of 40 mg/d predniso-
lone (S2 Fig). VFSS could not perform in any patients without clinical dysphagia.
Association between dysphagia involvement and clinical/laboratory
features
Firstly, we examined the association between the frequency of dysphagia involvement and clin-
ical or laboratory features by univariate analysis (Table 1). Most remarkable association was
detected between dysphagia and the existence of anti-TIF-1γ Ab or internal malignancy. Most
patients with dysphagia had internal malignancy (84.6%) or anti-TIF-1γ Ab (84.6%). And
this frequency was significantly higher than that of patients without them (10.1% and 19.0%,
respectively, p<0.0001). Age and the frequency of male/female ratio were significantly higher
in patients with dysphagia compared with patients without dysphagia (p<0.01). The manual
muscle testing (MMT) of neck (sternomastoid muscle) and shoulder (dertoid muscle) but
not hip (iliopsous muscle) was significantly lower in patients with dysphagia compared with
patients without dysphagia (p<0.05). The frequency of ILD was significantly lower in patients
with dysphagia compared with patients without it (p<0.01). Otherwise, there were no signifi-
cant differences between the frequencies of any clinical/laboratory features. Thus, dysphagia
was significantly more detected in aged or male patients, patients with internal malignancy,
anti-TIF-1γ Ab, and reduced MMT scores of sternomastoid and dertoid muscles or patients
without ILD.
Association between dysphagia involvement and clinical/laboratory
features in patients with anti-TIF-1γ Ab
We also evaluated the difference of clinical/laboratory features between patients with or with-
out dysphagia in DM patients with anti-TIF-1γ Ab (Table 2). The mean age and the ratios of
male to female and internal malignancy were significantly higher in patients with dysphagia
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compared with patients without dysphagia (p<0.05, p<0.05, and p<0.001, respectively). On
the other hand, the mean MMT scores of sternomastoid muscle were significantly lower in
patients with dysphagia compared with patients without dysphagia (p<0.05). Other clinical/
laboratory features were not significantly different between 2 groups.
Independent factors that were associated with the development of
dysphagia
Next, we evaluated clinical or laboratory factors that could closely associated with the develop-
ment of dysphagia in patients with DM by multivariate analysis. Investigated factors were as
follows; age, gender, interstitial lung diseases, internal malignancy, elevated CK, MMT scores
(sternomastoid, deltoid, and iliopsous muscle), anti-ARS Ab, and anti-TIF-1γ Ab. We per-
formed logistic regression analysis and the final model confirmed the significant risk factors
for the development of dysphagia in DM; internal malignancy (odds ratio 22.2), anti- TIF-1γ
Ab (odds ratio 11.8), and MMT score of sternomastoid muscle (odds ratio 0.46 for each score,
Table 3).
The profile of patients with dysphagia
Based on these findings, the profile of 13 patients with dysphagia was evaluated (Table 4). Ten
patients had both anti-TIF-1γ Ab and internal malignancy. Case 2 (56 year-old, female) was
positive for anti-TIF-1γ Ab but did not have internal malignancy. Case 4 (64 year-old, male)
with lung cancer was negative for anti-TIF-1γ Ab and positive for one kind of anti-ARS Ab
(anti-OJ Ab). Another case with dysphagia (case 11; 83 year-old, female) was negative for
known autoantibodies by immunoprecipitation assay and did not have malignancy. All
patients with dysphagia had muscle weakness and/or elevated serum CK levels. The sequence
Fig 1. Videofluoroscopy swallow study (VFSS). Videoradiographic sequence in a patient with
dermatomyositis (DM). A) Pharyngeal pooling is detected at both pharyngeal and esophageal phases. An
arrow indicates abnormal pooling of imaging agent. B) Nasal regurgitation is detected at pharyngeal phases
before treatment of DM. However, the observation was disappeared after treatment with corticosteroid. An
arrow indicates nasal regurgitation of imaging agent.
doi:10.1371/journal.pone.0154746.g001
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of symptoms such as skin, muscle, and dysphagia was not fixed in each patient. All 13 patients
showed clinical improvement of dysphagia after treatment of malignancy (n = 10) and DM
(corticosteroid therapy; n = 13 and intravenous immunoglobulin therapy; n = 2) during 7.3
±5.5 months period. Swallowing rehabilitation and balloon dilation were concurrently used in
11 cases and 1 case, respectively.
Among 10 patients with both anti-TIF-1γ Ab and internal malignancy, internal malignancy
was treated by both surgical operation and chemotherapy in 6 cases. The malignancy was
treated with surgical operation, chemotherapy, and radiation in each one case and another one
case could not receive any therapy for the malignancy. Only three cases achieved complete
remission of the malignancy.
Association between dysphagia and disease activity
To assess disease activity based on individual organ systems, MYOACT portion of the Myositis
Disease Activity Assessment Tool was used. The VAS scales of muscle disease activity, global dis-
ease activity score, but not global extra-skeletal muscle disease activity score were significantly
Table 1. Associations between dysphagia and clinical or laboratory features in patients with
dermatomyositis.
Dysphagia + (n = 13) Dysphagia − (n = 79)
Age 67.8±10.2** 52.8±16.1
Sex (male:female) 7: 6** 13: 66
Disease duration (month) 3.9±4.8 10.6±15.8
Symptom
Muscle weakness 92.3% 68.4%
MMT (sternomastoid) 2.8±1.1* 4.0±1.2
MMT (deltoid) 3.5±1.2* 4.3±0.9
MMT (iIliopsous) 3.7±0.9 4.1±0.9
Gottron's sign 92.3% 67.9%
Heliotrope rash 53.8% 43.6%
Interstitial lung diseases 7.7%** 52.6%
Internal malignancy 84.6%*** 10.1%
Laboratory ﬁnding
Elevated CK 92.3% 54.4%
Elevated KL-6 23.1% 47.4%
Autoantibodies
Anti-ARS antibody 7.7% 27.8%
Anti-TIF-1γ antibody 84.6%*** 19.0%
Anti-Mi-2 antibody 0% 3.8%
Anti-MDA-5 antibody 0% 19.0%
Anti-SS-A (Ro60) antibody 0% 6.3%
Anti-U1 RNP antibody 0% 6.3%
Anti-SRP antibody 0% 1.3%
MMT, manual muscle testing; CK, creatine kinase; KL-6, Krebs von den Lungen-6; ARS, aminoacyl-tRNA
synthetase; TIF-1γ, transcription intermediary factor 1γ; MDA-5, melanoma differentiation-associated
protein 5; RNP, ribonucleoprotein; SRP, signal recognition particle.
*p<0.05
**p<0.01
***p<0.0001 vs. patients without dysphagia
doi:10.1371/journal.pone.0154746.t001
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higher in patients with dysphagia compared with patients without it (p<0.01, Table 5). Among
global extra-skeletal muscle disease activity, the VAS scales of cutaneous disease activity score in
addition to gastrointestinal disease activity score were significantly elevated in patients with dys-
phagia compared with patients without it (p<0.05 and p<0.001, respectively). Thus, patients
with dysphagia showed higher muscle, cutaneous and global disease activity of DM.
Discussion
In this study, we detected a most significant association between the involvement of dysphagia
and the existence of internal malignancy or anti-TIF-1γ Ab. In addition, reduced MMT of ster-
nomastoid muscles was independent risk factor for the involvement of dysphagia.
There are literatures that have demonstrated the increased frequency of dysphagia in DM
patients with internal malignancy compared with patients without malignancy [4]. A recent
Japanese study demonstrated that proximal dysphagia, older age, and absence of interstitial
lung disease were independent risk factors for malignancy in Japanese patients with DM or PM
Table 2. Associations between dysphagia and clinical or laboratory features in dermatomyositis
patients with anti-TIF-1γ antibody.
Dysphagia + (n = 11) Dysphagia − (n = 15)
Age 66.8±9.9* 54.7±19.0
Sex (male:female) 6: 5* 1: 14
Disease duration (month) 4.4±5.1 5.0±6.1
Symptom
Muscle weakness 90.9% 53.3%
MMT (sternomastoid) 2.9±1.2* 4.0±1.2
MMT (deltoid) 3.6±1.0 4.3±1.5
MMT (iIliopsous) 3.7±1.0 4.2±1.0
Gottron's sign 81.8% 73.3%
Heliotrope rash 72.7% 80.0%
Interstitial lung diseases 0% 6.7%
Internal malignancy 90.9%** 20.0%
Laboratory ﬁnding
Elevated CK 90.9% 60.0%
Elevated KL-6 20.0% 20.0%
TIF-1, transcription intermediary factor 1; MMT, manual muscle testing; CK, creatine kinase; KL-6, Krebs
von den Lungen-6.
*p<0.05
**p<0.001 vs. patients without dysphagia
doi:10.1371/journal.pone.0154746.t002
Table 3. Multivariate analysis assessing the existence of dysphagia.
OR (95% CI) p value
Internal malignancy 22.2 (3.84 to 200.4) 0.0014
Anti-TIF-1γ Ab 11.8 (1.87 to 113.3) 0.0142
MMT (sternomastoid) 0.46 (0.20 to 0.95) for each score 0.0487
TIF-1, transcription intermediary factor 1; MMT, manual muscle testing
doi:10.1371/journal.pone.0154746.t003
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[5]. In consistent with these previous studies, the involvement of dysphagia was positively asso-
ciated with the involvement of internal malignancy by multiple regression in our population.
A recent systematic review and metaanalysis demonstrated that adult DM patients who
were positive for anti-TIF-1γ Ab had 27-fold higher odds ratio of having malignancy [11].
Therefore, the increased frequency of internal malignancy may be due to the secondary ten-
dency due to the existence of anti-TIF-1γ Ab in our study. Alternatively, the association
between anti-TIF-1γ Ab and dysphagia may be due to the correlation between internal malig-
nancy and dysphagia. In either case, our findings suggest that the existence of anti-TIF-1γ Ab
is one of the best indicators to estimate the development of dysphagia in adult patients with
DM, although previous studies did not evaluate this Ab. However, there is a phenotypic differ-
ence dependent on the age at onset among patients with this Ab. For example, juvenile patients
with this Ab do not develop malignancy [7, 21]. In fact, the mean age and ratios of male to
female were significantly higher in patients with dysphagia compared with patients without
dysphagia among patients with anti-TIF-1γ Ab (Table 2). Although multivariate analysis did
not define the aging or sex as an explanatory variable for the existence of dysphagia, further
large studies may be needed to clarify the significance of age or sex for the development of dys-
phagia. Thus, patients with either internal malignancy or anti-TIF-1γ Ab may develop dyspha-
gia more frequently compared with other patients.
A previous study demonstrated that the majority of DM patients with autoantibody against
small ubiquitin-like modifier activating enzyme develop cutaneous disease and progressed to
myositis with systemic features including dysphagia [22] The frequency has been reported as
8% (9/131 cases) in United Kingdom Caucasian adult-onset DM patients and the frequency of
dysphagia has been detected in 7 of 9 patients. This Ab was also detected in 1.5% (7/456 cases)
of Japanese DM patients and two of seven with this Ab had dysphagia [23].
Most patients with anti-TIF-1γ Ab exhibit DM with typical skin lesion and myositis, with-
out ILD [7, 8]. Our findings including MYOACT assessment also indicate that dysphagia
involvement tended to be associated with disease activity including global, muscle and skin in
addition to gastrointestinal tract in patients with DM. All 11 patients with dysphagia had ele-
vated CK levels and/or muscle weakness. However, a previous study demonstrated that clinical
assessment of muscle strength or disease activity can not be used to predict the risk of swallow
dysphagia in DM [24]. Our findings suggest that dysphagia develops in associated with multi-
ple factors. Therefore, it is possible that dysphagia may be found during the active phase of DM
if the patients had risk factors such as internal malignancy and/or anti-TIF-1γ Ab. Interest-
ingly, reduced muscle strength of sternomastoid muscles but not other muscles was indepen-
dent risk factor for the involvement of dysphagia, although sternomastoid muscles are close to
Table 5. Associations between dysphagia andmyositis disease activity scale.
Dysphagia (n = 13) No dysphagia (n = 79) p value
Muscle disease activity 35.4 ± 23.8 14.4 ± 17.5 <0.01
Global extra-skeletal muscle disease activity 17.8 ± 9.9 12.2 ± 6.8 ns
Constitutional disease activity 24.2 ± 23.1 12.3 ± 13.7 ns
Cutaneous disease activity 50.5 ± 19.9 30.5 ± 21.2 <0.05
Skeletal disease activity 1.0 ± 2.8 3.7 ± 7.7 ns
Gastrointestinal disease activity 11.9 ± 22.1 1.1 ± 3.7 <0.001
Pulmonary disease activity 8.1 ± 13.5 18.3 ± 20.9 ns
Cardiac disease activity 0.8 ± 2.8 1.5 ± 4.5 ns
Global disease activity 32.9 ± 17.5 18.4 ± 12.3 <0.01
doi:10.1371/journal.pone.0154746.t005
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the muscle of swallowing. Furthermore, the clinical symptoms of dysphagia disappeared after
the therapy against DM in all 13 patients. In a representative patient, VFSS was very useful to
observe the symptoms of dysphagia and to evaluate the effect of treatment.
The frequency of dysphagia was low in our cohort when compared with previous reports.
We assessed the existence at the presentation, although previous reports may include the devel-
opment of dysphagia during long clinical course. The definition of dysphagia may also differ-
ent, because we evaluated it by otorhinolaryngologists and speech therapists and confirmed
using VFSS. The mechanism of dysphagia of DM remains unclear. A recent study using VFSS
and manometry indicated that dysphagia in inflammatory muscle diseases may be due to
impaired muscle contraction and reduced hyolaryngeal excursion than the often held belief of
failed upper esophageal sphincter relaxation [25].
In our study, the number of patients, especially patients with dysphagia is small. Further
longitudinal studies in a larger population will be needed to clarify the associated factors for
the development of dysphagia in patients with DM.
Supporting Information
S1 Fig. Moving image of Fig 1 (case 1 of Table 4). Pharyngeal pooling is detected at both pha-
ryngeal and esophageal phases.
(MP4)
S2 Fig. Moving image of case 6 of Table 4. Anterior half; nasal regurgitation is detected at
pharyngeal phases before treatment of DM. Last half; the observation was disappeared after
treatment with corticosteroid.
(MP4)
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